TRAF members particularly TRAF6 are known key regulators of tumour‐promoting inflammation and immune response along TLR–NF‐κB pathway, therefore, small molecule inhibitors of TRAF6‐induced NF‐κB activating inflammation have been identified. Here, NFKB1 is linked to neoplasm.